Promising malaria and dengue vaccines alone will not defeat diseases; report

Despite the optimism surrounding two first-in-class products, Sanofi (Euronext: SAN) subsidiary Sanofi Pasteur’s live-attenuated dengue vaccine, CYD-TDV, and GlaxoSmithKline’s (LSE: GSK) adjuvanted subunit malaria vaccine, RTS,S/AS01, vaccination alone is not a viable long-term solution for combatting these infectious diseases, says an analyst.

According to Christopher Pace, research and consulting firm GlobalData’s managing analyst covering infectious diseases, some industry pundits rightfully question the modest protective efficacies of CYD-TDV and RTS,S/AS01. Immunization must therefore be leveraged alongside vector control strategies, national and international surveillance programs, and public awareness campaigns as part of integrated disease prevention and control initiatives.

Not a ‘silver bullet’ solution